BioMed Research International / 2015 / Article / Tab 3

Research Article

Hypoglycaemia, Abnormal Lipids, and Cardiovascular Disease among Chinese with Type 2 Diabetes

Table 3

Odds ratio of hypoglycaemia and lipid profiles for cardiovascular disease.

OR (95% CI) value

Hypoglycaemia for CVD
 Model one<0.0001
  Nonhyperglycemia Reference
  Mild hyperglycemia2.37 (1.72–3.26)
  Severe hyperglycemia5.80 (3.60–9.35)
 Model two<0.0001
  Nonhyperglycemia Reference
  Mild hyperglycemia2.64 (1.85–3.76)
  Severe hyperglycemia6.59 (3.79–11.45)
 Model three
  Nonhyperglycemia Reference<0.0001
  Mild hyperglycemia2.64 (1.85–3.76)
  Severe hyperglycemia6.59 (3.79–11.45)
Lipid profile for CVD
 Model four
  LDL cholesterol, mmol/L1.11 (1.01–1.24)0.0351
  HDL cholesterol, mmol/L0.69 (0.63–0.77)<0.0001
  Triglyceride, mmol/L1.12 (1.06–1.78)<0.0001
 Model five
  LDL cholesterol, mmol/L0.95 (0.84–1.07)0.3703
  HDL cholesterol, mmol/L0.89 (0.80–0.99)0.0299
  Triglyceride, mmol/L1.08 (1.02–1.14)0.0160
 Model six
  LDL cholesterol, mmol/L0.93 (0.82–1.05)0.2462
  HDL cholesterol, mmol/L0.87 (0.78–0.97)0.0097
  Triglyceride, mmol/L1.08 (1.01–1.14)0.0166

Model one: not adjusted for other variables.
Model two: adjusted for age, sex, BMI, systolic blood pressure and log-transformed urinary albumin to creatinine ratio, and drug use (statins, other lipid lowering drugs, renin-angiotensin system inhibitors, oral antidiabetes drugs [OADs] only, glucagon-like peptide-1 based treatment, basal insulin based treatment, and premixed insulin based treatment).
Model three: further adjusted for LDL-C, HDL-C, and triglyceride.
Model four: not adjusted for other variables.
Model five: adjusted for age, sex, BMI, systolic blood pressure, LDL-C, HDL-C, triglyceride and log-transformed urinary albumin to creatinine ratio, and drug use (statins, other lipid lowering drugs, renin-angiotensin system inhibitors, and oral antidiabetes drugs [OADs] only).
Model six: adjusted for the variables listed in model five and hypoglycaemia.

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.